Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Total revenues	$ 84	$ 39
Costs and expenses:
Production costs	270	268
Research and development	1,391	1,002
General and administrative	1,664	2,448
Total costs and expenses	3,325	3,718
Operating loss	(3,241)	(3,679)
Interest and other income	26	61
Redeemable warrants valuation adjustment	393
Gain (loss) on sales of short term marketable securities	1	(107)
Gain from sale of income tax net operating losses and research credits		1,561
Net loss	(2,821)	(2,164)
Other comprehensive income:
Reclassification adjustments for loss on sales of short term marketable securities included in net loss	(1)	107
Unrealized gain on marketable securities	12	40
Net comprehensive loss	$ (2,810)	$ (2,017)
Basic and diluted loss per share	$ (0.11)	$ (0.10)
Weighted average shares outstanding, basic and diluted	25,341,068	20,630,328
US [Member]
Revenues:
Clinical treatment programs	$ 23	$ 39
Europe [Member]
Revenues:
Clinical treatment programs	$ 61